Full Press Release Details
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer.
IMMP
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Key Takeaway: Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)